T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. The company is headquartered in Lexington, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2014-08-07. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The firm's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. The company also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.
Follow-Up Questions
Qui est le CEO de T2 Biosystems Inc ?
Mr. John Sperzel est le Chairman of the Board de T2 Biosystems Inc, il a rejoint l'entreprise depuis 2020.
Quelle est la performance du prix de l'action TTOO ?
Le prix actuel de TTOO est de $0.0035, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de T2 Biosystems Inc ?
T2 Biosystems Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de T2 Biosystems Inc ?
La capitalisation boursière actuelle de T2 Biosystems Inc est de $98175
Est-ce que T2 Biosystems Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour T2 Biosystems Inc, y compris 0 achat fort, 0 achat, 3 maintien, 1 vente et 0 vente forte
